New drug trial offers hope for patients with Tough-to-Treat blood cancer
NCT ID NCT06934044
Summary
This early-stage study is testing an investigational drug called cevostamab in a small group of Chinese patients whose multiple myeloma has returned or stopped responding to other treatments. The main goals are to understand how the drug behaves in the body, check its safety, and see if it can help control the cancer. This is a first step to see if the treatment is promising for this specific patient population.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of Nanchang University
RECRUITINGNanchang, China
-
The First Affiliated Hospital of Wenzhou Medical University
RECRUITINGWenzhou, 325035, China
-
Tianjin Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, Tianjin Municipality, 301636, China
-
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
RECRUITINGWuhan, 430030, China
Conditions
Explore the condition pages connected to this study.